In a nutshell
This study looked at the outcomes of different types of initial treatment for patients diagnosed with early stage mantle cell lymphoma. The study concluded that a reduced intensity treatment approach is worthwhile for patients with early stage mantle cell lymphoma.
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma. MCL is usually diagnosed at a late stage (stage III or IV). It rarely presents as early stage disease. Not much is known about the best way to treat patients diagnosed with early stage MCL. The most common types of treatment are chemotherapy (chemo), radiotherapy (RT), or a combination of chemo and RT. More research is needed to identify the best treatment for patients with early stage MCL.
Methods & findings
The medical records of 179 patients were reviewed. All patients were diagnosed with early stage MCL. 44 patients received chemo alone. 99 patients received chemo plus RT. 24 patients received RT alone. 12 patients were assigned to a watch-and-wait strategy. The average length of follow-up was 60 months.
The 10-year overall survival rate (time from treatment to death from any cause) for all patients was 64%. The 10-year overall survival for patients in the chemo only group was 69%. The 10-year overall survival rate for patients in the chemo plus RT group was 62%. The 10-year overall survival rate for patients in the RT only group was 74%. No treatment group was significantly better than any of the others.
The bottom line
The authors concluded that all treatment regimens had similar survival outcomes, so patients should be treated with reduced intensity treatment to reduce the possibility of later toxicities.
Published By :
Annals of oncology : official journal of the European Society for Medical Oncology
Sep 01, 2017
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?